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tion prescribed between July 2013 and June 2014. Results: Of 2,558 CHC treated 
patients, 142 patients (5.6%) were identified as having CKD . The mean age of CHC 
patients with CKD was 61 years compared to 57 years among those without CKD 
(p< .0001). Compared to CHC patients without CKD (n = 2,416), patients with CKD had 
significantly more comorbidities including diabetes (53% vs 23%, p< .0001), major 
depression (15% vs.6%, p= .0007), hypertension (85% vs. 51%, p< .0001) and heart 
failure (19% vs. 2%, p< .0001). CHC patients with CKD also had higher prevalence 
of kidney transplants (11% vs.1%, p< .0001) and more liver transplants (35% vs. 6%, 
p< .0001). For concomitant drug use, CHC patients with CKD had significantly more 
concomitant drugs (by drug class) during the 2-year baseline period compared to 
those without CKD (17 vs 11, p< .0001). Average annual out-of-pocket pharmacy 
expenses at baseline were significantly higher among CHC patients with CKD com-
pared to those without CKD ($1,079 vs. $606, p< .0001). ConClusions: In a US 
commercially insured population, treated CHC patients with CKD had significantly 
higher rates of comorbidities and drug utilization compared to those without CKD.
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objeCtives: To assess adherence in clinical practice of HIV patients switching to 
emtricitabina+tenofovir disoproxil+rilpivirin Methods: An observational retro-
spective cohort analysis, based on administrative databases from four Italian LHUs. 
The date of the first prescription of emtricitabina+tenofovir disoproxil+rilpivirin 
between January, 2010 and December, 2013 has been used as the index date. Patients 
were characterized back in previous 12 months to assess HIV treatments, and fol-
lowed up after index date for 12 months, date of death, or exiting the database 
(whatever came first). Non-adherence, as well as selective non-adherence, to antiret-
roviral medications were calculated using pharmacy refill compliance data in pre/
post index date period. Non-adherence measures were expressed in percentages of 
days spent either without all prescribed antiretrovirals (complete non-adherence) 
or without at least one of the prescribed regimen components (selective non-
adherence) on total days prescribed Results: During the observation period, 87 
patients switched to emtricitabina+tenofovir disoproxil+rilpivirin: 10 from Non-
Nucleoside Reverse Transcriptase Inhibitors (NNRTIs), 62 from efavirenz+emtricita
bina+tenofovir disoproxil (EFV/TDF/FTC) and 15 from Protease Inhibitors (PIs). Post-
switch non-adherence among the 87 patients switching to emtricitabina+tenofovir 
disoproxil+rilpivirin was around 4%, with small differences according to previous 
anti-retroviral therapies (4.7% in previously NNRTIs-treated, 4.2% in efavirenz+em
tricitabina+tenofovir disoproxil group and 3.2% in patients with previous PIs). For 
all of them, pre-switch non-adherence showed much higher values: from NNRTIs 
20.8% selective non-adherence, 30.5% to all drugs; from EFV/TDF/FTC 10.7%; from 
PIs 14.2% selective, 25.8% to all ConClusions: In this preliminary analysis, switch-
ing to emtricitabina+tenofovir disoproxil+rilpivirin increased treatment adherence 
with respect to previous therapies. This phenomenon was highly evident in patients 
coming from NNRTIs and PIs, who reported an absolute decrease in non-adherence 
rates of 46.6% and 36.8%, respectively
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objeCtives: The aim of this study is to determinate the minimum indicators to 
evaluate management and clinical results in institutions assisting patients living 
with HIV in Colombia, between different actors of the Health System. Methods: 
The Colombian Association of Infectology, health insurance companies, govern-
mental entities, international agencies and professionals leaders in attention of HIV 
patients were invited in order to have a consensus. Literature research in different 
databases like PubMed, Embase and Cochrane using Mesh terms was used. 3.023 
articles were found. After reading the titles 414 articles were selected, but finally 20 
articles were included. Experts reviewed the articles and raised indicators, then all 
system actors, selected the final indicators. Results: 17 indicators were selected 
and then classified in 4 groups. In the initial evaluation indicators included the 
proportion of patients with diagnosis of HIV who had attention with expert doc-
tors, patients with report of CD4, patients with viral load and patients with report 
of Lymphocytes. Monitoring indicators included the proportion of people with 
annual PPD, people with report of CD4 and viral load in the last 6 month, patients 
with annual syphilis screening and patients with cardiovascular risk assessment. 
Therapy indicators included the proportion of pregnant using anti-retroviral agents, 
patients with antitubercular agents. Furthermore, proportion of HIV people with 
undetectable viral load in the 48 weeks or more since the beginning of the treatment 
with antiretroviral agents, and others. Finally, the specific prevention indicators 
were related with people with latent tuberculosis treatment, prophylaxis for pneu-
monia by Pneumocystis Jirovecii and a proportion of people with complete vaccina-
tion schedule for Hepatitis B. ConClusions: Formulating indicators to institutions 
assisting patients living with HIV could decrease health inequalities in the attention 
of this population and will have a positive impact in HIV patients health results.
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ous stages. We perform sensitivity analysis in order to understand the attractiveness 
of various incentive schemes. Results: Once antibiotic development has success-
fully moved past the pre-clinical stages, incentives appear to not have all that much 
influence on investment decisions. At the pre-clinical stage, however, investment 
decisions are sensitive to incentives. Out of the incentives assessed, those rewarding 
success at the pre-clinical stage are the most effective at encouraging pre-clinical 
development. Incentives given further downstream are less attractive to develop-
ers due to the magnitude of upfront expenditure; the time value of money and 
associated development risks. ConClusions: A decision option approach to the 
valuation of antibiotics allows for a clear understanding of the value throughout the 
development cycle and allows us to assess the best structure for incentives aimed 
at encouraging antibiotic development.
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objeCtives: The aim of our examination was to evaluate knowledge of educated 
nurses on the prevention of infections due to inappropriate decontamination of 
nursing tools and patient environments and on nosocomialis infections and infec-
tion control. Methods: We carried out our cross-sectional, quantitative examina-
tion between 1.12.2014 and 28.02.2015 in 12 inpatient wards of a county hospital in 
Hungary. Our participants were educated nurses (N= 103), and for data collection we 
used two questionnaires: one with only closed-ended questions and one with only 
open-ended questions. We used Microsoft Office Excel 2002 software to carry out 
descriptive statistics, χ 2-test and two-sample t-test (p< 0.05). Results: On average, 
nurses scored higher in case of the questionnaire with closed-ended question that 
in case of the questionnaire with open-ended questions (p= 0.021). Average scores of 
nurses working at an intensive care ward was significantly higher than nurses work-
ing at other wards (p< 0.001). Nurses working in health care for longer time find the 
prevention of nosocomialis infections more important (p< 0.05). We found significant 
difference in case of the preparatory board, the PC keyboard, the patient’s bedside 
table, the telephone and the nurse-bell (p< 0.05), unlike in case of the door handle 
(p= 0.081). ConClusions: Knowledge of nurses on nosocomialis infections is not 
satisfactory at all fields. Nosocomialis infections occur the most often at intensive 
care wards, thus nurses working at that ward have the most extensive knowledge 
on the topic. Participants scored higher in case of the closed-ended questionnaire 
and chose the best answer more easily. Nurses do not consider the infectedness 
of the patient- or working environment highly important, although the play and 
important role in transferring nosocomialis infections.
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objeCtives: This study described patient characteristics and real world drug utili-
zation among patients diagnosed with CHC in the US. Methods: We conducted a 
retrospective database study using the Truven Health MarketScan® database. Patients 
were identified with ≥ 2 HCV medical claims (ICD-9: 070.54, 070.44, 070.70, 070.71) 
≥ 1 month apart (to define chronic illness), and had 3-year continuous enrollment 
in order to capture treatment experience. The CHC treated cohort was defined as 
those who had ≥ 1 HCV medication filled from 7/1/2013 to 30/6/2014. Results: 
Compared to untreated patients (n = 13,953), CHC treated patients (2,558) had a 
higher prevalence of liver transplants (7% vs 3%, p< .0001), cirrhosis (40% vs 20%, 
p< .0001), and comorbidities (Charlson Comorbidity index= 3.9 vs. 3.3, p< .0001). Of 
2,558 treated CHC patients, patients were treated by SOF/IFN/RBV (n= 580), SOF/RBV 
(n= 587), SOF/SMV (n= 511), INF/RBV (n= 342), BOC/IFN/RBV (n = 83), TEL/IFN/RBV 
(n = 162), and other regimens (n= 293). Across all the regimens, the mean age ranged 
from 53-59 years, and majority were male (60%-69%). Among patients receiving SOF/
IFN/RBV, SOF/RBV, SOF/SMV, INF/RBV, BOC/IFN/RBV or TEL/IFN/RBV therapy, cirrhosis 
was observed in 31%, 43%,55%,32%, 37%, and 28% respectively (p< 0.001). While the 
majority of patients treated with BOC/IFN/RBV (90%) or INF/RBV (69%) were HCV 
treatment experienced, only ~10% of patients with SOF-based regimen had prior 
HCV treatment (p< .0001). Patients treated with SOF/SMV had significantly more 
comorbidities compared to other regimens (p< 0.001); 13% of had prior liver trans-
plants compared to 7% of both SOF/RBV and INF/RBV patients and 2% of SOF/IFN/
RBV (p< .0001). ConClusions: In an insured population, treated CHC patients had 
higher rates of comorbidities and cirrhosis compared to untreated patients. While 
the majority of CHC patients with SOF-based regimen were treatment naïve, patients 
treated with SOF/SMV had higher comorbidities compared to other regimens.
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objeCtives: To compare patient characteristics and drug utilization among 
CHC patients with and without CKD in a US treated CHC population. Methods: 
De-identified, individual-level healthcare claims data from Truven Health 
MarketScan® database was analyzed. CHC was defined as those who had ≥ 2 medi-
cal claims of HCV (ICD9: 070.54, 070.44, 070.70, 070.71) ≥ 1 month apart. Three-year 
continuous enrollment was required in order to capture prior treatment experience. 
The CHC treated cohort was defined as those who had at least 1 HCV medica-
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population and economy against potentially troublesome and resource intensive 
outbreaks of infectious diseases.
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objeCtives: A new scenario of therapy for HCV infection is being established 
with the approval. The aim of this study is to evaluate the long-term health out-
comes and the willingness to pay of new anti-HCV treatment from the Italian soci-
etal perspective. Methods: A multistate model was developed to estimate the 
HCV-infection process in a theoretical cohort. The Markov process considered 
12 health states (F0, F1, F2, F3, Compensated cirrhosis (F4), SVR, decompen-
sated cirrhosis, HCC, Transplantation (1 year), Transplantation (years later), 
HCV-related death and death from other causes) and 42 transition probabilities. 
The model was informed with available data published in national and interna-
tional literature. Effectiveness of new treatment strategies was estimated from 
literature review. Cumulative cases of HCV-related diseases, direct and indirect 
medical costs, avoided by the increased effectiveness of new treatments, were 
estimated. Results: The cohort of subjects with chronic HCV in 2013 amounts 
to 267.190 subjects, of these about 17,600 patients F3-F4 are treated with drug 
therapy. Cumulative cases of HCV-related diseases who succeed in preventing by 
the increased effectiveness of new treatments amounted to 47.433 after 7 years, 
156.507 after 17 years, 256.942 after 27 years. The direct net medical costs, after 
the cost of the drug, amounted to € 18,13, € 72,33 and € 143,24 millions after 7, 17 
and 27 years respectively, and € 166,51, € 950,3 and € 551,53 attributable to indirect 
costs avoided, for the same time horizons. Furthermore, it was estimated that each 
patient treated with new drugs achieves a reduction of expenditure of about € 12,000 
in terms of direct costs, and € 4,000 in terms of indirect costs. ConClusions: In 
conclusion, an important share of the cost per treated patient can be compensated 
by the reduction of direct and indirect costs guaranteed by the effectiveness of new 
treatments.
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objeCtives: While the practice of Health Technology Assessment (HTA) has been 
well established there is wide variation in the processes by which public reimburse-
ment decisions for vaccines are made in comparison to medicines and devices. 
The objective of this study was to compare the assessments of vaccines across 
Europe (UK, France, Germany, Italy, Spain), and to critically appraise the systems 
using the key principles for the conduct of HTA (Drummond et al, 2008). Methods: 
A systematic review of economic modeling of vaccines, supplemented by a tar-
geted review of key stakeholder websites across Europe for previous assessments 
of vaccines was conducted. A search of Medline, Embase, Econlit and NHSEED was 
conducted and abstracts were reviewed by two independent reviewers against pre-
specified criteria for inclusion. Data from relevant articles was extracted and quality 
assessed. Country HTA websites were hand-searched. The evidence was synthesised 
to provide an overview of the strengths and weaknesses of the appraisal processes 
in each of the European countries. Results: The review highlighted the inher-
ent difficulties in health economic modeling using standard HTA processes as the 
long-term impact of vaccines is unknown, leading to wide variation in assumptions 
and methods of extrapolation. The literature identified highlighted the inherent 
uncertainty surrounding the long-term impact of vaccines, which directly impacts 
the cost-effectiveness. The review also highlighted the importance of budget 
impact of vaccines when making a decision. When compared to the key princi-
ples of HTA, all countries failed to meet all of the criteria. ConClusions: The 
economic evaluations identified indicated that the cost-effectiveness of a vaccine 
was heavily dependent on the assumptions surrounding uptake and carriage. The 
review indicated that HTA decisions on vaccines are driven by cost-effectiveness 
and budget impact, which may lead to underestimating the potential clinical and 
public health benefits.
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objeCtives: We performed national survey of behavior, attitudes and practice of 
general practitioners (GP) and specialists (pediatricians, ENT, pulmonologists) at 
the field of antimicrobial (ATB) use for respiratory tract infections. Methods: A 
34-item iPad iOS survey was performed personally with each GP and specialist 
during 7 months period. Results: The survey was completed by 357 GPs and spe-
cialists (61,9% and 38,1%, respectively). GPs and specialists were situated mostly in 
areas with population higher than 5000 people (49,3% and 48,5%), but GPs served 
significantly more often in area with population less than 5000 people compared 
to specialists (P< 0,001, CI 0,13 – 0,60). There was significantly higher number of GPs 
with practice shorter than 5 years compared to specialists (P< 0,01, CI 0,02-0,64). 
GPs used their own clinical experience in prescribing ATB more often compare to 
specialists (61,1% vs 43,4%, P< 0,01, CI 0,31-0,77) and specialist used more often ATB 
susceptibility reports compared to GPs (18,4% vs 8,1%, P< 0,01, CI 1,27-5,10), which 
also corresponds with frequency of checking susceptibility reports on monthly basis 
objeCtives: To document the proportion of national healthcare expenditures 
that is devoted to vaccines across Western Europe and its evolution over the past 
years. Methods: Seven countries were selected: the 5 biggest countries in terms 
of population accounting for ≈317 million inhabitants in 2015 (Germany, England, 
France, Italy, and Spain) and 2 smaller countries from northern and southern 
Europe: Sweden and Portugal. This panel of countries constitutes a good mix of 
vaccine procurement modalities (centralized/decentralized, tender/reimburse-
ment) across Western Europe. Data search was performed on both OECD online 
databases and national official sources for healthcare and vaccine expendi-
tures from 2008 (2006 for England) until the most recent year available (usually 
2012/2013). Results: Healthcare expenditures have increased in all countries 
but Spain. Increases ranged from +3%/year in France to+6%/year in England. In 
the meantime, despite heterogeneous availability, vaccine spending diminished 
markedly in Germany (9%/year from 2008 to 2013), Spain (-7%/year from 2008 
to 2012) and France (-4%/year from 2008 to 2013). Only Sweden (SEK 1.72 Bn in 
2013, +6%/year from 2011 to 2013) and England (£0.40 Bn in 2010/11, +14%/year 
from 2006/07 to 2010/11) have increased their spending on vaccines. The pro-
portion of healthcare expenditures allocated to vaccines ranged from 0.45% in 
Germany (€ 0.82/182.7 Bn in 2013) down to 0.25% in Spain (€ 0.17/ 68.6 Bn in 2012) 
and France (€ 0.63/248 Bn in 2013). When available, OECD data showed similar 
proportions and evolution patterns in most cases. ConClusions: Vaccination 
involves low levels of healthcare investments in Europe (< 0.5%) compared to 
the far-reaching public health benefits it procures. We evidenced a net trend 
towards a decrease over the past years, except for Sweden and England. In the 
ever-constraint budgetary context, vaccination budgets shall be preserved or even 
increased to sustain life-course approach of immunization at sufficient coverage 
rates.
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objeCtives: To compare the total value of payer’s expenditures on Victrelis 
(boceprevir) and Incivo (telaprevir) in patients with chronic HCV GT1 estimated in 
the manufacturers’ Budget Impact Analyses (BIAs) submitted with the reimburse-
ment applications to AOTMiT and actual expenditures of the National Health Fund 
(NHF). Methods: Annual public payer’s expenditures estimated in manufacturers’ 
BIAs for Victrelis and Incivo and actual expenditures reported by the NHF were com-
pared. RSSs were not taken into account. Analysed drugs were chosen on the basis 
of the same indication and financing through the same therapeutic programme 
in Poland. Actual expenditures and population size were taken from the finan-
cial reports of the NHF for the first and second year (actual data on 9 months for 
expenditures and 11 months for population size were extrapolated to one year) of 
reimbursement for each drug. Results: For drugs Victrelis and Incivo in patients 
with chronic HCV genotype 1 infections, the sum of total expenditures estimated 
in BIAs submitted with the reimbursement applications was 145,38 million PLN in 
the first year and 164,49 million PLN in the second year, and they were higher than 
the actual expenditures reported by the NHF: 77,48 million PLN and 120,72 million 
PLN, respectively. The expenditures estimated in BIAs were overestimated by 88% 
in the first year of reimbursement and 36% in the second year of reimbursement. 
Population size estimated in BIAs in comparison to its actual size from the NHF 
reports was overestimated by 53% in the first year and 38% in the second year 
of reimbursement. ConClusions: In the case of drugs chosen for this analysis, 
total payer’s expenditures estimated in BIAs submitted with the reimbursement 
applications were overestimated in comparison to the real life expenditures of 
the NHF in Poland.
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objeCtives: To assess the costs of vaccination throughout life for a fully immu-
nized Western European citizen. Methods: Vaccines recommended in the most 
recent National Vaccination Calendar (NVC) for Germany, England, France, Italy, 
Spain, Sweden and Portugal were used differentiating men from women and healthy 
individuals from those suffering from underlying condition(s) who require specific 
additional vaccinations. Unit vaccine costs and administration fees were retrieved 
from national official sources. The number of visits was adjusted for possible co-
administrations to better reflect local vaccination practices. All costs were calculated 
from the national healthcare perspective. In sensitivity analyses, vaccine costs were 
varied within a +/-30% range to account for possible price variations due to competi-
tion, market type, size and vaccines lifecycle. Administration fees were increased 
by 30% hypothesizing that medical fees are unlikely to decline over time. Results: 
Vaccinating an individual against up to 19 diseases throughout his entire life and 
in full compliance with NVC would range from € 350 to € 2,400 (vaccines costs only) 
and from € 450 to € 3,400 when administration costs are considered. Lowest range 
corresponds to healthy man in Sweden and highest range to woman with underly-
ing conditions in England. Vaccination costs were variable among countries due 
to heterogeneous NVCs and vaccination organization. In all countries but France, 
adults (18-64y) and elderly (≥ 65) accounted for the lowest vaccines costs com-
pared to pediatric (0-24m) and children/adolescents (2-17y). In comparison, other 
mass secondary prevention may be at least 3 times more costly. ConClusions: 
Vaccination requires a relatively low amount of money per individual knowing that 
some missed opportunities remain in senior vaccinations. A life-course approach 
of vaccination should be considered as a smart investment providing substantial 
benefit falling actually well beyond individual health and protecting the whole 
